and eliciting multiple responses by tumors and stroma. PAR-1 is thought to aid cancer progression and metastasis, 7, 8 however the role of the PAR-2, PAR-3, and PAR-4 in cancer is less defined. Whereas PAR-2 appears to have a wide distribution in various tissues and their tumors, PAR-1 often predominates in neoplasms when compared with their normal counterparts. 9 PARs belong to a unique family of G-protein-coupled receptors that are irreversibly modified by protease-mediated cleavage. Proteases that function as PAR activators cleave the extracellular N-terminus of a PAR, creating a novel N-terminal sequence that has affinity for the extracellular loops of the 7-transmembrane receptor. [10] [11] [12] As PAR-1, PAR-3, and PAR-4 are activated by thrombin, PAR-2 is a target of several serine-type proteases such as trypsin, tryptase, granzyme A, and coagulation factors (reviewed by Ossovskaya and Bunnett 13 ). Many molecular and biological effects mediated by the action of serine proteases through their respective PARs can be M etastatic tumors exhibit high levels of pericellular proteolysis, particularly at the advancing front, through expression of an array of proteases. 1 Serine proteases appear to be key regulatory instruments in pericellular proteolysis and have the ability to activate other zymogens, 1,2 deactivate biological modifiers, 3 and generate matricryptins from structural proteins of the extracellular matrix (ECM), 4 ,5 some of which are antiangiogenic. 6 In addition, serine proteaseactivated receptors (PARs) may function as sensors, signaling to cells the presence of extracellular serine proteases
Differential Effects of Serine Proteases on the Migration of Normal and Tumor Cells: Implications for Tumor Microenvironment
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The supporting role of proteases in tumor progression and invasion is well known; however, the use of proteases as therapeutic agents has also been demonstrated. In this article, the authors report on the differential effects of exogenous serine proteases on the motility of tumor and normal cells. The treatment of normal and tumor cells with a single dose of pancreatic serine proteases, trypsin (TR) and chymotrypsin (CH), leads to a concentration-dependent response by cells, first accelerating and then slowing mobility. Tumor cells are 10 to 20 times more sensitive to exogenous TR/CH, suggesting that a single dose of proteases may cause discordant movements of normal and tumor cells within the tumor environment. The inhibitory effects of TR on cell motility are contradicted by thrombin (TH), particularly in the regulation of normal cells' migration. The purpose of this investigation was to ascertain the role of protease-activated receptors (PARs) in terms of normal and tumor cell motility. Duplicate treatments with proteases resulted in diminished mobility of both normal and tumor cells. Repeated application of TR and TH in 1-hour treatment intervals initially desensitizes cell surface PARs. However, cell surface PARs reappear regardless of subsequent protease treatments in both normal and tumor cells. The resensitization process is retarded in tumor cells when compared with normal cells. This is evidenced by lower expression of PARs as well as by their relocalization at the tumor cell surfaces. Under these conditions, normal cells remain responsive to exogenous proteases in terms of cell motility. Exogenous proteases do not modulate motility of repeatedly stimulated tumor cells, and consequently, the migration of tumor cells appears disconnected from the PAR signaling pathways. The use of activating peptides in lieu of the cognate proteases for a given PAR system indicated that proteases may act through additional targets not regulated by PAR signaling. We hypothesize that the divergent migration patterns of normal and tumor cells due to exposure to proteases is in part mediated by PARs. Thus, treatment with exogenous proteases may cause rearrangement of the tumor and stromal cells within the tumor microenvironment. Such topographical effects may lead to the inhibition of tumor progression and metastasis development.
Keywords: trypsin; thrombin; protease-activated receptors; cell migration; cancer replicated with synthetic peptides, activating peptides (AP), which mimic the N-terminal ligand necessary for each PAR's activation.
As a result of PAR signaling, the cells undergo changes in shape, movement, secretion of regulatory molecules, and modulation of cell proliferation or apoptosis. 14, 15 We found that tumor cells in culture are sensitive to picomolar and nanomolar concentrations of exogenous trypsin and chymotrypsin (TR/CH) proteases and respond by diminished DNA synthesis, aggregation, and complete migratory stasis. 16 The same concentrations of exogenous proteases may stimulate normal cells to accelerated movement. The description of this remarkable difference in sensitivity to exogenous serine proteases between normal and tumor cells is the main purpose of this communication. We inquire whether the differential migratory response of normal and tumor cells to exogenous proteases is channeled through PARs. Under physiological conditions, the movement of normal cells is regulated so that migration halts when an appropriate cellular orientation is established. Little is known about mutual movement of tumor and normal cells within the tumor microenvironment, although the subject is clearly important for understanding tumor-stroma relationships that may drive or impede tumor growth. Coordinated movements involving stromal fibroblasts that form tracks in the ECM, which enable carcinoma cells to move in tandem, were recently described. 17 We suggest that the mutual disposition of tumor cells, normal cells, and the ECM at the tumor-stroma interface is influenced by exogenous proteases. Protease treatments that modulate stromal and tumor cell migration, therefore, would be expected to affect the ability of carcinoma cells to metastasize. The preponderance of the literature suggests that PAR-1 is the major conduit for extracellular protease-mediated induction of cell migration. 18, 19 The effectors of PAR-1 activation include thrombin, 20 MMP-1, 21 and plasmin. 22 Using TFLLRNPNDK and SLIGRL as specific agonist peptides, Shi et al 23 concluded that both PAR-1 and PAR-2 must be activated to permit movement of human melanoma cells. In contrast, Morris et al 24 suggested that PAR-2, activated by coagulation factors VIIa and Xa, is sufficient for cell migration. A negative role for PAR-1 was suggested by Kamath et al, 25 who found that thrombin and SFLLRN inhibited migration of MDA-MB-231 cells. Thus, it appears that both PAR-1 and PAR-2 may play a role in migration and/or invasion by tumor cells, and results may depend on the type of activating protease and experimental conditions.
A large effort has been directed toward the development of clinically useful protease inhibitors; however, only a few attempts were made to treat tumors with proteases. Yet it is the treatment with proteases that led to the inhibition or, in some cases, eradication of tumors and their metastasis in animals as well as patients. John Beard 26, 27 and some of his contemporaries conducted successful cancer treatment with crude extracts prepared from pancreas (see Novak and Trnka for citations 16 ). More recent preclinical and clinical trials used preparations consisting of trypsin, chymotrypsin, and other proteases for treatment of cancer 16, [28] [29] [30] [31] [32] and various pathologies. 33, 34 The mode of action by most of these preparations is not known; however, animal experiments using metastatic tumors indicate that cell migration and invasivity could be a target of the proenzyme therapy. 16 In this communication, we compared the effect of exogenous proteases and APs on linear movement of normal and tumor cells. We found that these effects depend on the type of protease, its concentration, and the method of application such as multiplicity of the treatments. Finally, we established that proteases appear to have additional targets as their effects on migration are not necessarily duplicated by cognate APs.
Materials and Methods

Materials
The following proenzymes and enzymes were all of bovine pancreas origin: trypsin (TR; Worthington Biochemical Corp, Lakewood, NJ, code TRLS), chymotrypsin (CH; Worthington, code CDI), trypsinogen (TG; Worthington, code TG; and Sigma, St Louis, MO, T1143), chymotrypsinogen A (CG; Worthington, code CGC; and Sigma, C4876). Activation peptides SLIGKV and SFLLRN were obtained from Bachem (Torrance, CA).
Cell Cultures
The following cells were obtained from ATCC (Manassas, VA): EA.hy926 (transformed human umbilical vein endothelial cells), MCF7 (breast carcinoma), MDA-MB-231 (breast carcinoma), MDCK (canine kidney normal epithelial cells), MG-63 (human osteosarcoma), PC-3 (human prostate carcinoma), and U-2 OS (human osteosarcoma). NRK-52E cells (normal rat kidney epithelial) were a generous gift from Dr Sally Nyquist (Bucknell University, PA). All cell lines were maintained in DMEM/F12 (DF) medium (Invitrogen, Carlsbad, CA) containing 10% fetal calf serum (Hyclone, SV30014). Cells were maintained at 37°C in 5% carbon dioxide and 95% air. All treatments with enzymes or proenzymes were conducted in serum-free DMEM/F12.
Reverse Transcriptase-Polymer Chain Reaction (RT-PCR)
Cell lines were harvested using TRIzol reagent (Life Technologies, Gibco BRL, Grand Island, NY) following the manufacturer's instructions. The concentration and purity of the RNA was determined with spectrophotometer readings at 280/260 nm. To remove genomic DNA traces still present in the RNA after isolation, deoxyribonuclease (Invitrogen) treatment was performed. The Superscript III first strand synthesis kit (Life Technologies, Gibco BRL) was used according to manufacturer's directions to synthesize cDNA for all PCR reactions. PCR was performed using Platinum PCR SuperMix (Invitrogen). Primers used for the PCR reactions were as follows: PAR-1 (human) 5′GTGCT-GTTTGTGTCTGTGCT3′ (forward), 5′CTTCTGTGGTG-GAAGTGTGA3′ (reverse); PAR-2 (human): 5′GGCCTT-GGCTGACCTCCTCC3′ (forward), 5′ATCATCAGCA-CATAGGCAGAGGC3′ (reverse); PAR-1 (rat): 5′CCCGCT-CATTTTTTCTCAGGAA3′ (forward), 5′CAATCGGTGCC-GGAGAAGT3′ (reverse); PAR-2 (rat): 5′AGAAGTCT-GATTGGCAGA3′ (forward), 5′CTTCTGTGGTGGAAGT-GTGA3′ (reverse); β-actin (human and rat): 5′ATCT-GGCACCACACCTTCTACAATGAGCTGCG3′ (forward), 5′CGTCATACTCCTGCTTGCTGATCCACATCTGC3′ (reverse).
Amplification cycles consisted of 94°C for 30 seconds and 35 cycles of the following: 94°C for 30 seconds, 72°C for 50 seconds. The PCR reaction was performed on a PCR thermocycler (MJ Research, Waltham, MA). The products of the PCR were analyzed electrophoretically on a 1.5% agarose gel with ethidium bromide.
Cell Migration Assays
The cells were grown to confluency in 48-well or 24-well plates and maintained an additional 24 hours past confluency before subjected to washing with serum-free DF 2 to 3 times. The monolayers were wounded with a sterile pipette tip and washed again twice times to remove dislodged cells and debris. Control wells received warm (37°C) DF media (antibiotic and serum free). The experimental wells received DF media containing enzymes or other constituents at concentrations indicated in the figure legends. The wounded monolayers were incubated at 37°C, 5% CO 2 environment and monitored for progress in closing the wound gap during the next 6 to 24 hours depending on the cell type. The cells were fixed with 4% formaldehyde and stored at 4°C until photographs were taken with a phase contrast microscope (Nikon Eclipse TE200) at 40× magnification. Care was taken to obtain several exposures at the standard location of the wound with respect to the well. The most representative exposures were selected for the evaluation of the experimental conditions under study.
Western Blotting
Cells were rinsed once in ice-cold phosphate buffered saline (PBS) and dissolved in a 2× Electrophoresis Sample Buffer (Santa Cruz Biotechnology, Santa Cruz, CA, sc-24945) and boiled for 10 minutes. The protein content of all lysates was measured and 30 μg of each sample was loaded on a 10% polyacrylamide/SDS-PAGE gel (Bio-Rad, Hercules, CA). The separated proteins were transferred by electroblotting (80 mA, 1 hour) onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA). The membrane was blocked with TBS buffer containing 0.05% Tween 20 (TBS/Tween) and 5% nonfat dry milk for 2 hours at room temperature and probed with either the primary antibody rabbit polyclonal anti-PAR-1 (Santa Cruz Biotechnology, sc-5605) or mouse monoclonal anti-Par-2 (Santa Cruz Biotechnology, sc-13504) overnight at 4°C. Both antibodies target activating cleavage sites of the respective PARs. Membranes were washed 3 times for 10 minutes each with TBS/Tween before addition of the goat antirabbit IgG-HRP (Santa Cruz Biotechnology, sc-2004) or goat antimouse IgG-HRP (Santa Cruz Biotechnology, sc-2031). Incubation of the secondary antibody was performed for 1 hour at room temperature. Membranes were washed 3 times for 10 minutes each with TBS/Tween. After washing, the immunocomplexes were reacted with a chemiluminescence reagent (SuperSignal West Dura ECL, 34075; Thermo Scientific, Waltham, MA) and the immunoreactive bands were recorded using a Kodak IS440 image station.
Immunocytochemistry
Cells were fixed with 3.5% paraformaldehyde for 20 minutes at room temperature and blocked with PBS with 1% goat serum (Santa Cruz Biotechnology, K-1607) for 30 minutes. Cells were incubated at a 1:125 dilution with rabbit polyclonal Par-1 (Santa Cruz Biotechnology, sc-5605) and mouse monoclonal Par-2 (Santa Cruz Biotechnology, sc-13504) for 2 hours followed by 3 washes with PBS. The slides were incubated for 30 minutes with the secondary antibodies Alexa Fluor 488 goat anti-mouse IgG antibody (Invitrogen, 20 μg/mL) and Alexa Fluor 568 goat antirabbit IgG antibody (Invitrogen, 20 μg/mL). Samples were incubated at room temperature in the dark for 30 minutes, rinsed 3 times, mounted with DAPI (Vectashield; Vector Laboratories, Burlingame, CA), and viewed at 60× using a Nikon Eclipse E800.
receptor. Normal human kidney cells (HK-2) and normal endothelial-like EA.hy926 cells appear to be lower in PAR expression when compared with tumor cells. RT-PCR of normal rat kidney cells (NRK-52E) was performed using species-specific primers for PAR-1 and PAR-2. Although NRK-52E cells express both PAR-1 and PAR-2 equally, the expression level of PAR-1 appears to be lower than in the tumor cells. The expression of both PAR-1 and PAR-2 by MDCK cells was recently shown by Saifeddine et al. 35 This screen was intended to confirm that PAR-1 and PAR-2 proteins are expressed in the cells chosen for our experiments.
Biphasic Effect of Serine Proteases on Linear Motility of Normal and Tumor Cells
Various cell lines were evaluated for their migratory response to exogenous proteases. Typical results obtained with representative normal (MDCK) and tumorigenic (PC-3) cell lines are shown in Figure 2A . The results demonstrate that treatments with low nanomolar concentrations of proteases lead to acceleration of cell movement, whereas higher concentrations result in slower cell migration and eventually cell stasis. Normal cells are approximately 10 times less sensitive to enzymes when compared with tumor cells in both stimulatory and inhibitory stages of the migration response. This supports the previous suggestion that treatment of juxtaposed normal and tumor cells with the same concentration of protease may bring about discordant migratory responses by such cells. 16 Similar effects were obtained with proenzymes ( Figure 2B ) providing that they were supplied in substantially higher concentrations, particularly to normal cells.
We concluded that cells of normal or tumor origin are affected by proteases with respect to their movement. Generally, cell movement was accelerated at very low protease concentrations, whereas at higher concentrations the cells moved substantially slower until becoming static. Conversion from acceleration to inhibition of migration occurs within a narrow range of protease concentrations. For neoplastic cells this conversion occurs at ≅50 ng/mL TR/CH and in normal cells at ≅200 ng/mL TR/CH. Thus, when compared with normal cells, the neoplastic cells appear to be more sensitive to exogenous proteases.
Repeat Treatment of Normal Cells With Proteases Leads to Inhibition of Cell Migration
The differential effect of proteases on tumor and normal cells was established in cultures treated with a single dose continuously for the duration of the gap healing (8-14 hours, dependent on cell type). In vivo, however, the protease levels may change rapidly as a response to intercellular interactions or following therapy. We adopted a regimen consisting of wounding, followed by one to four 30-minute protease treatments and 6 to 12 hours of continuous treatment with media alone or a 100 ng/mL TR/CH mixture. First, we addressed the question of whether cellular motility is dependent on the concentration of the enzymes used during the initial 30-minute pulse with proteases. To test this, normal NRK-52E cells were exposed to various concentrations (12.5-400 ng/mL) of TR/CH during the pulse, then washed and transferred into serum-free media with or without TR/CH (100 ng/mL; Figure 3 ). The cells posttreated with media (DF) alone travel at rates comparable with the controls (cells maintained in DF for the entire time course). However, cells treated 30 minutes with increasing levels of TR/CH and posttreated with 100 ng/mL TR/CH exhibited slower migration. Thus, repeat protease treatment abrogates accelerated movement of NRK-52E cells that occurs following a single protease treatment (Figure 2) . A similar decline in migration was observed with protease-treated tumor cells (results not shown). 
Preincubation With Trypsin Alone Results in Abrogation of Accelerated Cell Migration by Normal Cells
We established that a single treatment of normal cells with TR/CH may lead to accelerated migration ( Figure 2 ) whereas repeat treatment leads to migration stasis ( Figure 3 ). To identify which of the two proteases is responsible for these phenomena, the cells were preincubated with either TR or CH at 1000 ng/mL for 30 minutes and then transferred into DM (control; single protease treatment) or into TR/CH mixture (double protease treatment) for the remainder of the migration experiment. Preincubation with TR (100-1000 ng/mL) alone, but not CH, leads to loss of a mechanism that governs accelerated movement of the normal cells (Figure 4 ). Further tests with normal cells revealed that the process is (a) concentration dependent on the level of the first trypsin treatment and (b) reliant on a trypsin concentration of at least 5 nM during the entire migration experiment.
We conclude that normal cells, when preincubated with TR but not with CH, lose their ability to move rapidly during a subsequent incubation with the TR/CH mixture. Enzyme treatments containing TR only (or TR and CH) lead to the same result, thus indicating that the repeat exposure to TR is unique in its effects on cell migration. As trypsin is known to activate the PAR-2 receptor, we hypothesize that this result is because of modulation of PAR-2 at the surface of the affected cells.
Multiple Treatment With Proteases Decouples PARs From the Control of Tumor Cell Movement
The cleavage of PARs by their cognate proteases leads to activation of specific signaling pathways and desensitization of the receptors. 36 We decided to visualize, by means of immunocytochemistry, the presence of activatable PARs at the surface of protease-treated nonpermeabilized cells. We define activatable PARs by their ability to bind antibodies directed at their cleavage site. For these experiments, we used thrombin (TH) as the activating protease for PAR-1 and trypsin as the activating protease for PAR-2.
In preliminary experiments, we found that the addition of proteases rapidly clears the majority of full-length PARs from cell surfaces with replenishment of the membranelocalized receptors being observed within 1 to 2 hours. We hypothesized that repeat exposure of cells to proteases may cause long-term depression of cell surface-localized PARs. It was of interest to investigate the possibility that cell migration could be attenuated by disallowing cell surface PAR receptors to recover after an initial treatment with either TR or TH. For this purpose, the cells were treated with three 1-hour spaced applications of TR or TH (100 ng/mL TR and 0.5 U/mL TH). Figure 5 reveals that the initial treatment of normal and tumor cells with proteases depressed PAR-1 and PAR-2 cell surface receptors. A period of 1 hour after the first protease application was not sufficient to allow for a recovery of the cell surface receptors. Surprisingly, subsequent hourly treatments with proteases did not lead to a complete loss of PARs from cell surfaces. Control experiments, assessing status of PARs at 30 minutes after each protease application, confirmed low surface levels (results not shown). We conclude that when under repetitive protease stress both normal and tumor cells acquire the capacity to rapidly relocate PARs to the cell surface. The migration of cells treated with four 1-hour protease pulses is shown in Figure 6 . In accordance with the results shown above, the migration of EA.hy926 cells was inhibited in a TR-enriched environment and promoted following TH treatments. In contrast, tumor PC-3 cells exhibited migration that did not differ substantially from the control cells. TR did not retard and TH did not promote the migration of tumor cells. The conclusion from several similar experiments is that normal cells when repetitively treated with proteases retain PAR-mediated control over motility whereas the tumor cells become unresponsive.
Repeat treatments with proteases did not permanently clear PARs from the surface of treated cells as expected. Semiquantitative analysis of PARs was, therefore, performed on cells subjected to the same repeat treatments with TR and TH, as depicted in Figure 5 . Western blot analysis did not detect any gross quantitative changes in PARs following the multiple treatments with proteases ( Figure 7 ). This suggests that the total cellular levels of PAR-1 and PAR-2 have not changed, although a change in the distribution of PARs between cytoplasm and cell membrane may have taken place as evidenced by immunochemistry ( Figure 5 ).
In summary, the effects of repeat protease treatments may include disconnection of PAR-mediated signaling from cellular migration in tumor but not normal cells. These data indicate that multiple protease treatments desensitize cells to the proteolytic pressure via rendering cell surface receptors nonresponsive or dysregulated, particularly in the tumor cells. As a result, we propose that the extended presence of proteases in the cellular environment retards cellular migration of tumor cells. 
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TR and AP2 Exert Divergent Effects on Movement of Tumor Cells
Activating peptides are synthetic peptides resembling a tethered NH2-terminal ligand created by cleavage of PARs by their cognate proteases. We therefore expected the effects of serine proteases on cell migration to be duplicated by PAR's APs. TR alone has a biphasic effect on migration of tumor cells as shown above (Figure 1 ). AP2 (SLIGKV), a specific activator of PAR-2, is widely used to mimic the effect of trypsin-like proteases. The migration of PC-3 tumor cells treated with trypsin, SLIGKV alone, and in combination is shown in Figure 8 . Contrary to our expectations, AP2 increased movement of PC-3 cells in a concentrationdependent manner. The movement of normal cells was also stimulated by AP2 (results not shown). However, when AP2 and TR/CH were applied simultaneously, the impact on cellular migration was similar to the effects of the TR/CH mixture alone. The reason for this observed dichotomy of actions between TR and AP2 is not known; however, it appears that the effect of TR is dominant over that of AP2.
AP1 (SFLLRN) Promotes Migration of Tumor Cells and Counteracts the Effect of TR/CH
We found thrombin to promote the migration of both normal and tumor cells and to attenuate trypsin-mediated inhibition of tumor cell migration ( Figure 9 and Novak, unpublished results). We reasoned that the effect of thrombin is mediated by activation of PAR-1, and therefore, it should be duplicated by a treatment with AP1 (SFLLRN). Wounded monolayers of PC-3 cells were treated with a range (5-320 μM) of AP1 alone ( Figure 9A ) or in combination with TR/CH (25-400 ng/mL; Figure 9B ). AP1, when tested alone, strongly supported the movement of PC-3 tumor cells in a concentration-dependent manner. Addition of AP1 strongly attenuated the migration inhibitory effect caused by a treatment with TR/CH (400 ng/mL). The results of this experiment suggest that AP1 may play a protective role against the inhibitory effects of TR/CH on the migration of tumor cells. Figures 8 and 9 demonstrate that both AP1 and AP2 peptides support cell migration in the wound assays. The effect of AP1 resembled the effect of thrombin. In contrast, the effects of AP2 and TR on wound healing in tumor cells were diametrically different. The combined effect of AP1 and AP2 was previously found necessary for movement of melanoma cells. 23 The effect of these 2 peptides on the movement of normal (HK-2) and tumor (U-2 OS) cells is shown in Figure 10 . AP1 and AP2 when used separately caused accelerated migration in both types of cells, confirming the results shown above. Surprisingly, when used in a mixture, the APs induced a concentration-dependent inhibition of wound closure in both types of cells. 
Experiments shown in
Thrombin Promotes Migration of Normal and Tumor Cells and Opposes Negative Effects of Trypsin on Cell Migration
Thrombin is a ubiquitous component of tumors (see Discussion) and exerts strong procarcinogenic and proangiogenic activities. We have identified TR to inhibit the migration of both normal and tumor cells, particularly if applied repetitively. It is, therefore, likely that the effect of TR could be contradicted by thrombin. Metastatic breast cancer MDA-MB-231 cells treated with TH (0.5 U/mL) immediately after wounding exhibited enhanced migration and nearly complete closure of the wound ( Figure 11A ). As expected, low concentrations of TR (100 ng/mL), without accompanying CH, had little effect on migration of tumor cells, although it clearly depressed cell density of the cultures. These negative effects of TR were strongly attenuated in assays containing both TH and TR. Thus, the presence of TH increased both survival and migration of the MDA-MB-231 cells.
Similar experiments with normal MDCK ( Figure 11B ) cells showed that their migration was not significantly affected by TR (100 ng/mL) concentrations but became strongly inhibited by a double exposure to TR as described previously. Surprisingly, the combination of TH and TR produced very strong promigratory effects by these cells and led to near closure of the wounds. These results revealed the possibility that within the tumor microenvironment the ratio between TH and TR may have a decisive impact on the behavior of the stromal and tumor cells.
Discussion
Exogenous serine proteases may affect the conditions in the pericellular space either through activation of PARs or directly through proteolysis of cellular or ECM component(s). The importance of the proteolytic/antiproteolytic balance in progression of cancer has been invoked previously, identifying exaggerated proteolysis as a detriment to the tumor growth or metastasis. 16, 37 In this communication, we concentrated on the question of whether the use of exogenous proteases affects cell motility and whether this effect is mediated by PARs. We found that (a) single treatments with serine proteases (TR/CH) differentially regulate motility of normal and tumor cells in wound repair essays, (b) in comparison to normal cells the movement of tumor cells is highly sensitive to the exogenous proteases, (c) repeat treatments with proteases cause inhibition of cell motility in both normal and tumor cells, (d) chronic protease treatment may cause refractoriness of tumor cells to proteases in terms of cell migration, and (e) APs and proteases are not equivalent in terms of their effect on cell motility in vitro.
Differential Sensitivity of Normal and Tumor Cells' Motility to Exogenous Proteases
Demonstration that a single dose of proteases may concurrently enhance migration of normal cells and inhibit that of tumor cells (see Figure 2 ) offers a possibility to affect diversely the normal and tumor cells within a tumor microenvironment. Achieving graded sensitivity of normal and tumor cells is one of the most desirable properties of a presumptive cancer drug. The mechanisms underlying the differential effects of the same enzyme preparation on the migratory behavior of normal and tumor cells are not understood. The following possibilities are currently considered: (a) presumed primary targets of proteases, the PARs, may signal differently in tumor and normal cells; 8 (b) normal and tumor cells may have divergent mechanisms governing PAR desensitization and resensitization processes; 38 and (c) serine proteases may interact with other cellular or ECM targets that may vary qualitatively and quantitatively between normal and tumor cells. The latter could involve PARmediated activation of integrins 39 or direct attack of proteases on cell surface or ECM constituents. 40 It is well established that optimal cell adherence, based on integrin number, type, and affinity for a given substrate, is required for maximal cellular migration. 41, 42 Our observations concerning the differential effect on normal and tumor cells were specific for TR and the TR/CH mixture. We found thrombin to promote migration of both normal and tumor cells. In other studies, thrombin inhibited 25 or enhanced 18, 19, 43 tumor cell migration and invasivity. Further experiments showed that serial treatment with 2 or more protease applications resulted in slower migration by both normal and tumor cells. It occurred to us that repeated application of proteases could be responsible for attenuation of invasive and metastatic properties of tumor cells. Several mechanisms may account for the loss of migration following repeat treatments of cells with proteases. First, repeat protease treatment could cause activation of many pericellular proteases, leading to exaggerated proteolysis. 37, 44 Second, chronic presence of proteases could result in refractoriness to exogenous proteases, possibly through dysregulation of cell surface PARs. 45 Finally, constant proteolytic stress could lead to a disconnection between PARs (and/or other protease target molecule) and the cell motility system.
Proteases, PARs, and APs in Cell Movement
The historical reference for using a mixture of trypsin(ogen) and chymotrypsin(ogen) as antitumor agents is based on the work of John Beard and his coworkers who used crude pancreatic extracts. 27 Nevertheless, evidence-based rationale in favor of this combination is yet to be developed. Both trypsin and chymotrypsin proved essential in cell aggregation experiments and induction of apoptosis. 16 Trypsin is the principal protease of the PAR-2 system and appears to be the causative agent responsible for the changes in cell migration described in this communication. A chymotrypsin-sensitive site in PAR-1, upstream of the activating bond, requires micromolar concentrations of the enzyme 46 and thus is not likely to proceed under physiological conditions. Alternatively, chymotrypsin could be endocytosed and become part of a recently described apoptotic pathway. 47 In our experiments, CH did not activate PAR-2, and preincubation with CH did not preclude effects of TR/CH on cell migration (Figure 4) .
Effective trypsin concentrations that either promote or inhibit cellular migration fall into a range of 0.5 to 20 nM. The effects of exogenous proteases are often validated by APs, short peptides derived from a novel amino end of PARs created by protease cleavage. On a molar basis, as much as 5000 times higher levels of AP1 are required to equal the effect of thrombin on calcium fluxes in human brain microvascular endothelial cells. 48 In addition, compared with thrombin, AP1 (SFFLRN) causes a more sustained rise of Ca 2+ that is dependent on a high level of extracellular calcium. Thus, activation of PARs by enzymes and by APs may use different signaling pathways. We found that the effect of thrombin and its cognate AP is compatible and that both agents are permissive for cell movement. However, the effect of trypsin and that of AP2 (SLIGKV) on cell movement is clearly contradictory. Shintani et al 49 reported contraction of myometrium by trypsin but not by AP2 and suggested the existence of a novel trypsin-activated receptor. We found thrombin or AP1 to attenuate the effects of trypsin on cell migration. Moreover, application of both AP1 and AP2 peptides resulted in slower rather than faster migration (Figure 10 ).
These results are contrary to those reported by Shi et al, 23 who suggested that both AP1 and AP2 must be present to promote chemotaxis by melanoma cells toward fibronectin.
It is recognized that various activating proteases and APs may cross-activate other than their relevant receptors. In addition, various proteases were found to inactivate PAR receptors. 50 Thus, the SFLLRN peptide activates not only PAR-1 but also PAR-2. 35 The fidelity of AP2 (SLIGKV) as an activator of PAR-2 has also been questioned. 12, 51 Finally, evidence suggests that PARs may form heterodimers and may cross-activate each other.
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Multiple Proteolytic Stress and the Ability of Cells to Migrate
Exposure of PARs to their cognate proteases causes receptor activation, rapid desensitization by endocytosis, and recycling or degradation in lysosomes. 53 The replenishment of PARs at the cell surface occurs by 2 processes, mobilization of formed PAR-2 from intracellular storage and by de novo synthesis. Downregulation of PARs by APs has been studied to a lesser extent. Brass et al 54 visualized SFLLRN-mediated internalization of PAR-1 receptors using only permeabilized cells. A confocal microscopy study of the AP-induced trafficking of transfected PAR-2 has also been reported. 55 Finally, the treatment with SLIGKV (100 μM) and TH (4 U/mL) removed 60% of PAR-2 and PAR-1 cell surface receptors, respectively. 56 Cross-desensitization of PAR-1 and PAR-2 receptors was not noted, even though trypsin at higher concentrations can cleave PAR-1. 57 A substantial residual response to SFLLRN remains after exposure of cells to trypsin, which may be because of activation of additional PAR-2 58 or activation of some other member of the PAR family. Mirza et al 59 described a complete recovery of PAR-2 receptors 45 minutes after treatment of endothelial cells with SLIGRL. We observed similar kinetics (45-90 minutes) of recovery of PAR-1 and PAR-2 following a single treatment with an agonist. This was accompanied by a bipolar effect on cell migration in both normal and tumor cells (see Figure 2) . Very different responses in terms of the cell movement and the status of cell surface PARs were obtained when wounded monolayers were treated with 4 successive protease applications. Such cells should theoretically regenerate most of their PARs during intervening periods. This did not occur at the end of the first hour, but the presence of PARs was noted at the end of subsequent treatments, particularly in normal cells ( Figure 5A ). In contrast, tumor cells are unable to fully recover their PARs after multiple protease treatments ( Figure 5B ). This is documented by both quantitative (intensity of cell surface fluorescence elicited by specific PAR antibodies) and changes in cell surface distribution of PARs. We intend to describe the nature of these receptors in the future. We hypothesize that such receptors, particularly in the tumor cells, become disconnected from cognate signaling pathways and exert little effect on cell migration. We conclude that PARs can exist at the cell surfaces in a functional or nonfunctional state and that only the former has the ability to convert the presence of protease into changes in cellular motility.
Is Thrombin an Oncogene and Trypsin a Tumor Suppressor Factor?
The results indicate that the negative effect of TR and TR/CH on cell migration can be attenuated by thrombin. The contradictory effects of TH and TR were particularly evident in all the normal cells tested. The reason for these contrasting effects is not known; however, accumulating evidence supports the view that the PAR-1 and PAR-2 systems balance each other in several aspects of their biological activities. The notion that PAR-1 may be an oncogene was first raised by Whitehead et al 60 by showing that its cDNA can transform NIH-3T3 fibroblasts. Recently, Martin et al 61 suggested that transformation by thrombin may proceed through activation of Rho-mediated pathway. The possibility that trypsin (and by extension PAR-2) may function as a tumor suppressor was first proposed by Yamashita et al. 62 Long-term studies of hypercoagulability established that the presence of increased thrombin and fibrin fragments in the blood predicts higher incidence of cancer. 63 Thrombin has been shown to activate platelet tumor aggregation and increase development of metastasis. 7, 64 These thrombin tumorigenic actions are mediated by thrombin activation of PAR-1 and ensuing changes in cell-cell and cell-substrate adhesiveness. 65 Thrombin has also been linked to stimulation of tumor migration and invasivity 66 and angiogenesis. 67 In other studies, however, thrombin had no effect on chemotaxis of breast cancer cells. 19, 25 The interest in trypsin-mediated protective and antiinflammatory actions 68 has been rejuvenated in recent years through observations that PAR-2 protects from damage caused by coronary ischemia-reperfusion injury 69 and attenuates gastric ulcer development. 70 In addition, SLIGRL has been shown to curb inflammation caused by LPS in airway passages 51, 71 and in pancreatitis. 72 These effects contrast with proinflammatory effects of TH in a variety of systems. 73 In this work, we described that TH reverses trypsin-mediated inhibition of normal cell migration. It is possible that this antagonism extends to attenuation of TR-mediated inhibition of tumor cell proliferation and DNA synthesis. 16, 74 In pancreatic cancer, PAR-2 is highly expressed in tumors that exhibit severe fibrosis, 75 and fibrosis is often associated with poorer prognosis. 76 Thus, it appears that TR or the TR/CH mixture may function in tumors as an antidote to thrombin and limit its proinvasive and proliferative effects. We hypothesize that TH neutralizes anti-invasive effects of TR in most tumor microenvironments. Future studies will concentrate on the generation of TH within tumors and the possibility that TH is an important limiting factor to a successful use of pancreatic proteases in tumor therapy.
Cell Movement, Proteases, and Tumor Microenvironment
During embryogenesis and normal repair and renewal processes cell movement is under multiple strict controls that include proteases. 77 Tumors are increasingly recognized as self-organizing organs, 78 and thus, as in any other organ/tissue, the mutual disposition of cells is paramount to their function. 79 We have discovered that different cellular components that comprise tumors possess differential sensitivity to exogenous proteases in terms of their migration. We argue that proteases administered either as a bolus or in repeat applications should lead to disturbances in the spatial balance between stroma, tumor cells, and the ECM.
The cooperation between normal and tumor cells extends to migration, 17 as carcinoma cells were found to travel in tandem behind track-forming fibroblasts. The movement of cells depends in part on integrin expression 80 and affinity, 39 which in turn may be regulated by proteases. Consequently, proteases may affect cellsubstrate and cell-cell interactions through changes in cell movement. Encounters between fibroblastic cells of the connective tissues with epithelial cells of tumor origin must be common during metastatic progression. Omelchenko et al 81 identified several steps that occur during a meeting of fibroblastic and epithelial cells. The process includes initial overlapping of the lamellas followed by their retraction with the formation of lamellas elsewhere in the fibroblastic cells, leading to a pull-away motion by the fibroblasts. It is thus clear that heterotypic interactions require motility to take place and result in a positional readjustment of the cells. It is possible that this realignment is influenced by extracellular proteases. Thrombin is omnipresent in tumors, particularly at the growing front. We propose that antimigratory effects of pancreatic serine proteases are potently opposed by thrombin and that these interactions determine the degree of growth and invasivity at the particular tumor microenvironment. Furthermore, it appears that thrombin and trypsin exert their effect through tumor stroma, as well as through a direct effect on the tumor cells. The discordant movement of the normal and tumor cells could result in disturbances within the tumor microenvironment and therefore affect tumor invasivity as well as microvascular support. Finally, it should be possible, at least in theory, to exploit such stark differences in protease-controlled motility by normal and neoplastic cells for a treatment of metastatic cancer.
